Logo image of ANNX

ANNEXON INC (ANNX) Stock Fundamental Analysis

NASDAQ:ANNX - Nasdaq - US03589W1027 - Common Stock - Currency: USD

1.88  -0.03 (-1.57%)

Premarket: 1.8404 -0.04 (-2.11%)

Fundamental Rating

3

ANNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. While ANNX has a great health rating, there are worries on its profitability. ANNX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANNX had negative earnings in the past year.
In the past year ANNX has reported a negative cash flow from operations.
ANNX had negative earnings in each of the past 5 years.
ANNX had a negative operating cash flow in each of the past 5 years.
ANNX Yearly Net Income VS EBIT VS OCF VS FCFANNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -39.48%, ANNX is in line with its industry, outperforming 56.36% of the companies in the same industry.
With a decent Return On Equity value of -47.15%, ANNX is doing good in the industry, outperforming 65.72% of the companies in the same industry.
Industry RankSector Rank
ROA -39.48%
ROE -47.15%
ROIC N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ANNX Yearly ROA, ROE, ROICANNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANNX Yearly Profit, Operating, Gross MarginsANNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANNX has more shares outstanding
ANNX has less shares outstanding than it did 5 years ago.
ANNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANNX Yearly Shares OutstandingANNX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ANNX Yearly Total Debt VS Total AssetsANNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ANNX has an Altman-Z score of -1.14. This is a bad value and indicates that ANNX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.14, ANNX is in line with its industry, outperforming 59.54% of the companies in the same industry.
ANNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.14
ROIC/WACCN/A
WACCN/A
ANNX Yearly LT Debt VS Equity VS FCFANNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 10.37 indicates that ANNX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.37, ANNX belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
ANNX has a Quick Ratio of 10.37. This indicates that ANNX is financially healthy and has no problem in meeting its short term obligations.
ANNX has a better Quick ratio (10.37) than 80.57% of its industry peers.
Industry RankSector Rank
Current Ratio 10.37
Quick Ratio 10.37
ANNX Yearly Current Assets VS Current LiabilitesANNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ANNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.70%, which is quite impressive.
EPS 1Y (TTM)42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 32.67% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.66%
EPS Next 2Y-15.33%
EPS Next 3Y8.59%
EPS Next 5Y32.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANNX Yearly Revenue VS EstimatesANNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANNX Yearly EPS VS EstimatesANNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANNX Price Earnings VS Forward Price EarningsANNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANNX Per share dataANNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.33%
EPS Next 3Y8.59%

More info and screens

0

5. Dividend

5.1 Amount

ANNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNEXON INC

NASDAQ:ANNX (4/25/2025, 8:00:00 PM)

Premarket: 1.8404 -0.04 (-2.11%)

1.88

-0.03 (-1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-19 2025-05-19
Inst Owners101.97%
Inst Owner Change0.04%
Ins Owners0.53%
Ins Owner Change15.03%
Market Cap206.25M
Analysts84.29
Price Target14.48 (670.21%)
Short Float %8.11%
Short Ratio4.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.44%
Min EPS beat(2)-20.16%
Max EPS beat(2)5.28%
EPS beat(4)3
Avg EPS beat(4)6.55%
Min EPS beat(4)-20.16%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)9.82%
EPS beat(12)10
Avg EPS beat(12)11.71%
EPS beat(16)10
Avg EPS beat(16)6.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.37%
PT rev (3m)-6.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS2.67
TBVpS2.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.48%
ROE -47.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.37
Quick Ratio 10.37
Altman-Z -1.14
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.39%
Cap/Depr(5y)92.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y-25.66%
EPS Next 2Y-15.33%
EPS Next 3Y8.59%
EPS Next 5Y32.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-35.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.59%
OCF growth 3YN/A
OCF growth 5YN/A